Reference List - Gore Medical

G r e a t L e g sg e t r e s u l t s
OCCLUSION
0.65%
BEFORE
KINKING
0.43%
AFTER
P E R F O R M A N C E t h r o u g h d a t a
A PubMed ® search of all EVAR literature since 2001 generated 12 peer-reviewed publications 1 that
report on limb patency and / or limb kinking for EVAR devices and met basic criteria for inclusion in
this literature review. The inclusion criteria for these publications was a minimum of 40 patients and
follow-up of greater than one year.
GORE ® EXCLUDER ® AAA Endoprosthesis legs provide the flexibility and long-term conformability
that have been shown to maintain patency in more challenging patient anatomies. A unique
combination of advanced sinusoidal stent design, ultra smooth ePTFE graft material, and sutureless
attachment between the two enables these legs to flex in challenging / tortuous vessels.
Legs crossed or uncrossed — with GORE ® EXCLUDER ® AAA Endoprosthesis you choose the best
option for your procedure and your patient.
1
For the complete list of references, please visit www.goremedical.com/AAAgreatlegs.
INDICATIONS FOR USE: Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components. The GORE EXCLUDER ®
AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic
aneurysm (AAA) disease and who have appropriate anatomy as described below: adequate iliac / femoral access, infrarenal aortic neck
treatment diameter range of 19 – 29 mm and a minimum aortic neck length of 15 mm, proximal aortic neck angulation < 60°, iliac artery
treatment diameter range of 8 – 18.5 mm and iliac distal vessel seal zone length of at least 10 mm. Aortic Extender Endoprosthesis and
Iliac Extender Endoprosthesis Components. The GORE EXCLUDER ® Extender Endoprostheses (Aortic and Iliac) are intended to be used
after deployment of the GORE EXCLUDER ® AAA Endoprosthesis. These extensions are intended to be used when additional length and
/ or sealing for aneurysmal exclusion is desired. Contraindications: There are no known contraindications for these devices. Refer to
Instructions for Use at goremedical.com for a complete description of all warnings, precautions and adverse events.
W. L. Gore & Associates, Inc. • Flagstaff, AZ 86004 • goremedical.com
Products listed may not be available in all markets. GORE ® , EXCLUDER ® , PERFORMANCE THROUGH DATA, and designs are trademarks of
W. L. Gore & Associates. ©2010 W. L. Gore & Associates, Inc. AP0395-EN3 SEPTEMBER 2010

1. Bos WTGJ, Tielliu IFJ, van den Dungen JJAM, et al. Results of endovascular abdominal aortic aneurysm repair with selective use of the
Gore Excluder. Journal of Cardiovascular Surgery 2009;50(2):159-164.
2. Bos WT, Tielliu IF, Sondakh AO, Vourliotakis G, Bracale UM, Verhoeven EL. Hybrid endograft solution for complex iliac anatomy: zenith
body and excluder limbs. Vascular 2010;18(3):136-140.
3. Carroccio A, Faries PL, Morrissey NJ, et al. Predicting iliac limb occlusions after bifurcated aortic stent grafting: anatomic and devicerelated
causes. Journal of Vascular Surgery 2002;36(4):679-684.
4. Haider SE, Najjar SF, Cho J-S, et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic
endoprosthesis: 12-month comparison to the original Excluder device. Journal of Vascular Surgery 2006;44(4):694-700.
5. Hingorani AP, Ascher E, Marks N, et al. Iatrogenic injuries of the common femoral artery (CFA) and external iliac artery (EIA) during
endograft placement: an underdiagnosed entity. Journal of Vascular Surgery 2009;50(3):505-509.
6. Maleux G, Koolen M, Heye S, Nevelsteen A. Limb occlusion after endovascular repair of abdominal aortic aneurysms with supported
endografts. Journal of Vascular & Interventional Radiology 2008;19(10):1409-1412.
7. Maynar M, Zander T, Qian Z, et al. Bifurcated endoprosthesis for treatment of aortoiliac occlusive lesions. Journal of Endovascular
Therapy 2005;12(1):22-27.
8. Mendonça CT, de Carvalho CA, Weingärtner J, et al. Endovascular treatment of abdominal aortic aneurysms in high-surgical-risk patients
using commercially available stent-grafts. Journal of Endovascular Therapy 2010;17(1):89-94.
9. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS. Five-year report of a multicenter controlled clinical trial of open versus
endovascular treatment of abdominal aortic aneurysms. Journal of Vascular Surgery 2007;45(5):885-890.
10. Pfammatter T, Lachat ML, Künzli A, et al. Short-term results of endovascular AAA repair with the Excluder Bifurcated Stent-Graft. Journal
of Endovascular Therapy 2002;9(4):474-480.
11. van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, Harris PL, Buth J, Laheij RJF; EUROSTAR collaborators. Risk-adjusted outcome analysis of
endovascular abdominal aortic aneurysm repair in a large population: how do stent-grafts compare? Journal of Endovascular Therapy
2005;12(4):417-429.
12. Verhoeven ELG, Tielliu FJ, Prins TR, et al. Frequency and outcome of re-interventions after endovascular repair for abdominal aortic
aneurysm: a prospective cohort study. European Journal of Endovascular Surgery 2004;28(4):357-364.
W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004
+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)
goremedical.com
Products listed may not be available in all markets.
GORE, EXCLUDER ® , and designs are trademarks of W. L. GORE & Associates.
© 2010 W. L. GORE & Associates, Inc. AP0618-EN1 SEPTEMBER 2010